Growing at compound annual growth rate (CAGR) of 3%, the global asthma and chronic obstructive pulmonary disease (COPD) market is expected to reach US$50 billion by 2022. The US and China accounted for 81% of the global market in 2016. Top contributing factors to market growth include an increasing ageing population, technology advancement, and greater improvement of diagnostic methods. In 2018, a study conducted by Tulane University found that the second leading cause of death in China is COPD, with more than 100 million people affected. Furthermore, due to a smoking rate of over 50% smoking rate in China and worsening levels of air population, there is an anticipated unmet medical need of respiratory sickness and diseases. Overall, the China market for asthma and COPD is very attractive in terms of growth and need.
Project ID: COPD100
Keywords: re-open the collapsed small airways
Project COPD110 has developed a new device for the treatment of COPD. For the last 50 years, there have been no significant advances in COPD treatment. Standard of care treatment for COPD is primarily by inhaled bronchodilators. However, these drugs only target the upper airways, and much of COPD is caused by the collapse of small airways.
The company’s Pulsehaler™ technology is the first and only treatment to directly re-open the collapsed small airways of COPD patients, thereby reducing breathlessness and improving patient’s ability to walk. The Pulsehaler™ technology produces unique multi-frequency, air pressure pulses which are carried into the lungs, gently prying open the airways, lowering the viscosity of mucus that could re-plug the airway, and stenting the airway open to allow the airway clearance mechanisms to function properly. The technology was clinically proven in a double blind controlled study, and published in the peer reviewed Journal of COPD. Our technology is protected by 6 patent families, with 15 issued patents and 9 additional pending patents.
The company’s technology pipeline also includes patented designs for improving delivery of inhaled drugs. This technology was clinically proven to deliver drugs more than 200% better than traditional nebulizers, with significant improvements in lung function. We have begun initial discussions with Pharma companies to partner in the development of Best-in-Class inhaled therapies, including COPD, Cystic Fibrosis, Asthma, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension.
Indications: COPD, Cystic Fibrosis, Asthma, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension.
Partnering Objective: Series B fundraising $ 10 Million, Licensing, Joint-venture